Atlas market file · Equity · United States
Neogenomics IncNEO
- Last close
- 1.836
- Change
- -0.60%
- 96-bar range
- 1.786 – 3.403
- As of
- 7 Aug 2026
Neogenomics Inc is a services-testing laboratories issuer listed as NEO on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
NEO
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-80.04% over the window).
Source rail: Binance spot klines (NEO/USDT). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NEO. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
NEO public profile
Services-testing laboratories issuer. Neogenomics Inc is connected to current market context, cited company sources and its retained research file.
Neogenomics Inc trades as NEO on NASDAQ. Neogenomics Inc (NEO) has a latest verified close of 1.836, down 0.60%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NEO under USA Stocks and Science & Biotech Stocks for browsing.
What changed for Neogenomics Inc today
NeoGenomics, Inc. (NEO) revealed a settlement agreement on July 20, 2026, via an 8-K/A filing, though specifics remain opaque. The company, a cancer diagnostics firm with labs in the U.S. and U.K., reported a net loss of $17.1M and negative operating cash flow of $8.1M in its Q1 2026 10-Q filing, despite holding $146.1M in cash and $29.8M in inventory. The settlement comes amid ongoing financial pressures, including $517.8M in liabilities and a 1.3M increase in inventory balances.
NeoGenomics operates as a cancer genetics testing provider, offering services through CAP-accredited labs. Its financials, however, tell a tale of strain: R&D costs reached $9.5M in Q1 2026, exceeding its net cash from operations. The June 25, 2026, appointment of Carolyn Starrett to the board was framed as a strategic win, yet the company’s diluted shares outstanding now total 129.2M, raising questions about dilution risks amid weak cash generation.
The company’s June 22, 2026, indenture establishes terms for debt redemption, requiring $100M in notes to remain outstanding if partial redemptions occur. This structure underscores NeoGenomics’ reliance on debt financing, even as its stockholders’ equity sits at $828.8M-paper wealth that contrasts with the $5M spent on capex and a $1.3M inventory build in Q1. The lack of positive free cash flow raises concerns about sustainability.
NeoGenomics’ recent filings reveal a pattern of cash outflows exceeding inflows, with operating activities consuming $8.1M in Q1. The company’s $146.1M cash reserves provide a buffer, but the trend is clear: without improved operational performance, the balance sheet will continue to tightening. The market’s response to these filings has been muted, though the stock’s liquidity remains tied to its NASDAQ listing and institutional ownership dynamics.
Key risks include the company’s inability to generate positive operating cash flow, inventory buildup ($29.8M vs. $28.5M in prior periods), and reliance on debt instruments. Catalysts could emerge from resolution of litigation (per the July 20 settlement), board changes, or updates to its diagnostic service offerings. However, absent a material improvement in core earnings, NeoGenomics remains a high-risk biotech play.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NEO technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-29. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NEO
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NEO research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NEO FAQ
What is Neogenomics Inc (NEO)?Neogenomics Inc (NEO) has a latest verified close of 1.836, down 0.60%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed...
Neogenomics Inc (NEO) has a latest verified close of 1.836, down 0.60%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NEO?Neogenomics Inc (NEO) has a latest verified close of 1.836, down 0.60%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Neogenomics Inc (NEO) has a latest verified close of 1.836, down 0.60%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NEO under USA Stocks and Science & Biotech Stocks for browsing.
How often is the NEO page updated?The NEO public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NEO public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NEO?The NEO file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NEO. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The NEO file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NEO. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NEO?Yes. The workstation can open NEO, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NEO, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NEO page investment advice?No. The NEO page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NEO page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →